Bulaquine

Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A). Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria[1][2][3].

Research Areas >> Infection

Bulaquine (40 mg/kg; p.o. once) affects multiple pathways in vivo[1]. Bulaquine (1.25 mg/kg; once daily; for 7 days) shows 100% curative anti-relapse activity with a primaquine index of 0.8 for rhesus monkeys with Plasmodium cynomolgi B infection[2]. Animal Model: 25-30 g male Swiss albino mice[1] Dosage: 40 mg/kg Administration: Oral gavage; 40 mg/kg once Result: Affected oxidative stress and fatty acid synthesis pathway, apoptosis, cell cycle, inflammatory response, glycogen metabolism, Kreb’s cycle, electron transport chain, fatty acid β-oxidation, MAPK signalling, signalling of hepatocyte growth factor receptor, matrix metalloproteinases, steroid biosynthesis, TGF-β signalling, translation factors, Wnt signalling, regulation of actin cytoskeleton, ribosomal proteins, RNA transcription reactome, proteasome degradation and nuclear receptors in lipid metabolism according to GO results.